News – Page 1179 – Endpoints News

Regulus craters after FDA slaps a hold on hep C RNA drug following 2nd case of jaundice

9 years ago

Third time the charm? Analyst says a marketing decision is “imminent” for Sarepta’s Duchenne drug eteplirsen

9 years ago

Bristol-Myers’ nivolumab grabs its sixth breakthrough designation as new links to autoimmune diseases creep up

9 years ago

GW Pharma’s rally rolls on as cannabinoid drug scores again in PhIII Epidiolex anti-convulsive study

9 years ago

The Zerhouni rule: “Every company that acquires a platform company kills it.”

9 years ago

Scoring the 5 top phase III drugs in the global pipeline

9 years ago

IPO bound? CRISPR Therapeutics ups B round to a cool $140M

9 years ago

Medivation to Sanofi (in translation): You don't know beans about cancer drug development(!)

9 years ago

What’s ahead for UK biotechs in the wake of Brexit? It's not a pretty picture

9 years ago

These 300(+) Biotech Twitter citizens are the quickest to tweet news

9 years ago

VC giant NEA backs an upstart’s plan to tackle neurodegeneration

9 years ago

Ebola! Zika! ATM! Inovio CEO Kim called out for gaming pandemic panic

9 years ago

Zombie biotech Eleven Bio sheds staff in the final wind down

9 years ago

Is Biogen the most desperate buyer scouting the biotech market?

9 years ago

Celgene pays $50M to tie up with four big cancer research centers

9 years ago

Gary Glick gets $27M to leap back into immuno-oncology R&D with Novartis, Atlas and Abingworth in his corner

9 years ago

Pluristem uses the preclinical hype gambit to whip up a quickie stock gain

9 years ago

$121M later, Langer-backed Selecta raises $70M more from its IPO

9 years ago

Antifungal player F2G banks $60M, eyes IPO in leadup to a PhIII trial

9 years ago

Sean Parker finds a big role to play in cancer R&D: The disruptive billionaire

9 years ago

Savara hunts cash after doubling down on late-stage respiratory drugs

9 years ago

Novartis takes aim at a slate of blockbusters with cheaper biosimilars

9 years ago

Circassia shares crumble as PhIII flop blights the sector once again

9 years ago

Epizyme says it’s excited by PhII data, but there’s plenty to fret about

9 years ago

First page Previous page 1176 1177 117811791180 Next page Last page